On June 18, Abbott Laboratories fell 3.02% in regular trading, trading at approximately $87.99/share, with turnover of $7.82 billion.

On the news front, an investment bank lowered its target price on Abbott, adding downward pressure to the stock. Meanwhile, the Health Care Equipment sector experienced broad-based selling, amplifying Abbott's decline. The current analyst consensus rating on Abbott remains at Overweight, with an average target price of $115.50, well above the current trading level.

Within the Health Care Equipment sector, major peers declined sharply on the same session: Medtronic fell 4.35%, Boston Scientific fell 4.29%, Intuitive Surgical fell 3.86%, and Stryker fell 3.53%. The collective sector weakness compounded the negative sentiment stemming from the target price revision. Abbott operates across four business segments including Diagnostic Products, Nutritional Products, Medical Devices, and Established Pharmaceutical Products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)